|
|
|
Stem Cell Related Patent Number US6916470
| Title: | Methods for use of mpl ligands with primitive human stem cells | | Inventors: | Murray, Lesley J.; San Jose, CA, USA
Young, Judy C.; Mountain View, CA, USA | | Summary: | Described herein are methods of use for myeloproliferative leukaemia (mpl) receptor ligands, such as thrombopoietin. The invention relates to the action of such mpl ligands on a primitive subpopulation of human stem cells having the characteristics of self-renewal and the ability to give rise to all hematopoietic cell lineages. The thrombopoietin mpl ligand has been found to support both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (namely, CD34+Lin-, CD34+Thy-1+Lin-, and CD34+Lin-Rh123lo), while also stimulating quiescent human stem cells to begin cycling. Further disclosed are methods by which mpl ligands are useful for the restoration of hematopoietic capabilities. Therapeutic applications in gene therapy are provided. | | Abstract: | Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations (CD34+Lin−, CD34+Thy-1+Lin−, and CD34+Lin−Rh123lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6916470 | | Application Number: | US2001000052879 | | Date Filed: | 22/10/2001 | | Date Published: | 12/07/2005 | | Assignee: | Novartis AG, Basel, Switzerland |
|
|
